Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA.
J Clin Oncol. 2011 Mar 1;29(7):925-33. doi: 10.1200/JCO.2009.27.2369. Epub 2010 Nov 15.
In the past decade, we have witnessed important gains in the treatment of ovarian cancer; however, additional advances are required to reduce mortality. With compelling evidence that ovarian cancers are immunogenic tumors, immunotherapy should be further pursued and optimized. The dramatic advances in laboratory and clinical procedures in cellular immunotherapy, along with the development of powerful immunomodulatory antibodies, create new opportunities in ovarian cancer therapeutics. Herein, we review current progress and future prospects in vaccine and adoptive T-cell therapy development as well as immunomodulatory therapy tools available for immediate clinical testing.
在过去的十年中，我们见证了卵巢癌治疗方面的重要进展；然而，为了降低死亡率，还需要进一步的进展。有确凿的证据表明卵巢癌是免疫原性肿瘤，因此应该进一步探索和优化免疫疗法。细胞免疫疗法在实验室和临床操作方面的显著进步，以及强大的免疫调节抗体的发展，为卵巢癌治疗带来了新的机会。在此，我们综述了目前在疫苗和过继性 T 细胞治疗开发方面的进展和未来前景，以及可立即进行临床测试的免疫调节治疗工具。
